降低IBD患者的林蛋白增加了凝血风险,但新的Rac1抑制剂显示出有前途. Reduced layilin protein in IBD patients raises clotting risk, but new Rac1 inhibitors show promise.

研究人员发现,流行性肠道疾病(IBD)患者的主要蛋白质(苯丁胺)水平较低40%,通常能防止血凝结。 Researchers found that patients with Inflammatory Bowel Disease (IBD) have a 40% lower level of a key protein, layilin, which normally prevents blood clotting. 这导致由于凝结增加,心脏病发作和中风的风险增加。 This leads to a higher risk of heart attacks and strokes due to increased clotting. 然而,目前其他条件临床试验中的药物,即称为Rac1抑制剂的药物,在减少人类和动物模型中的过量凝块作用方面显示了希望,有可能改善综合症综合管理,同时又不会增加出血风险。 However, drugs currently in clinical trials for other conditions, known as Rac1 inhibitors, showed promise in reducing excessive clotting in both human and animal models, potentially improving IBD management without increasing bleeding risks.